Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1991 Nov 15;88(22):10208–10212. doi: 10.1073/pnas.88.22.10208

Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

C Garret 1, A Carruette 1, V Fardin 1, S Moussaoui 1, J F Peyronel 1, J C Blanchard 1, P M Laduron 1
PMCID: PMC52897  PMID: 1719549

Abstract

We describe here the pharmacological properties of RP 67580 [(3aR,7aR)-7,7-diphenyl-2-[1-imino-2-(2-methoxyphenyl)ethyl] perhydroisoindol-4-one], a nonpeptide antagonist of substance P (SP). In vitro, the compound was found to inhibit in a competitive manner (Ki = 4.16 +/- 0.59 nM) [3H]SP binding to neurokinin receptors type 1 (NK1 receptors) in rat brain membranes. Contractions induced by SP and septide (a selective NK1 agonist) in guinea pig ileum were competitively inhibited by RP 67580 (pA2 = 7.16 and 7.59, respectively). Moreover, RP 67580 displayed the profile of a specific antagonist of NK1 receptors: it was not active on NK2 and NK3 receptors as seen in binding assays and in isolated preparations of rabbit pulmonary artery and rat portal vein. In the rat, low intravenous doses of RP 67580 totally inhibited the plasma extravasation induced by SP in the urinary bladder (ED50 = 0.04 mg/kg i.v.) and by antidromic electrical stimulation of the saphenous nerve in the hind paw skin (ED50 = 0.15 mg/kg i.v.). This compound was also active in two classical analgesic tests in mice: phenylbenzoquinone-induced writhing (ED50 = 0.07 mg/kg s.c.) and the formalin test (ED50 = 3.7 mg/kg s.c.). Its potency was of the same order as that of morphine. Thus we conclude that RP 67580, a SP antagonist, belongs to a class of drugs that may be useful in the management of various clinical pathologies where pain and neurogenic inflammation are involved.

Full text

PDF
10208

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abelli L., Somma V., Maggi C. A., Regoli D., Astolfi M., Parlani M., Rovero P., Conte B., Meli A. Effects of tachykinins and selective tachykinin receptor agonists on vascular permeability in the rat lower urinary tract: evidence for the involvement of NK-1 receptors. J Auton Pharmacol. 1989 Aug;9(4):253–263. doi: 10.1111/j.1474-8673.1989.tb00216.x. [DOI] [PubMed] [Google Scholar]
  3. Bergström L., Beaujouan J. C., Torrens Y., Saffroy M., Glowinski J., Lavielle S., Chassaing G., Marquet A., D'Orleans-Juste P., Dion S. 3H-neurokinin A labels a specific tachykinin-binding site in the rat duodenal smooth muscle. Mol Pharmacol. 1987 Dec;32(6):764–771. [PubMed] [Google Scholar]
  4. Björkroth U., Rosell S., Xu J. C., Folkers K. Pharmacological characterization of four related substance P antagonists. Acta Physiol Scand. 1982 Oct;116(2):167–173. doi: 10.1111/j.1748-1716.1982.tb07126.x. [DOI] [PubMed] [Google Scholar]
  5. D'Orléans-Juste P., Dion S., Mizrahi J., Regoli D. Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium. Eur J Pharmacol. 1985 Aug 7;114(1):9–21. doi: 10.1016/0014-2999(85)90515-1. [DOI] [PubMed] [Google Scholar]
  6. Gitter B. D., Waters D. C., Bruns R. F., Mason N. R., Nixon J. A., Howbert J. J. Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol. 1991 May 17;197(2-3):237–238. doi: 10.1016/0014-2999(91)90532-u. [DOI] [PubMed] [Google Scholar]
  7. Guard S., Watson S. P., Maggio J. E., Too H. P., Watling K. J. Pharmacological analysis of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum longitudinal muscle-myenteric plexus and cerebral cortex membranes. Br J Pharmacol. 1990 Apr;99(4):767–773. doi: 10.1111/j.1476-5381.1990.tb13004.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hunskaar S., Fasmer O. B., Hole K. Formalin test in mice, a useful technique for evaluating mild analgesics. J Neurosci Methods. 1985 Jun;14(1):69–76. doi: 10.1016/0165-0270(85)90116-5. [DOI] [PubMed] [Google Scholar]
  9. LITCHFIELD J. T., Jr, WILCOXON F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949 Jun;96(2):99–113. [PubMed] [Google Scholar]
  10. Laduron P. M., Verwimp M. F., Janssen P. F., Gommeren W. R. Tissue fractionation in rat brain, kidney and liver. I. Intracellular localization of a 5-methyltetrahydrofolic acid requiring enzyme. Biochimie. 1975;57(2):253–260. doi: 10.1016/s0300-9084(75)80172-6. [DOI] [PubMed] [Google Scholar]
  11. Laufer R., Gilon C., Chorev M., Selinger Z. [pGlu6,Pro9]SP6-11, a selective agonist for the substance P P-receptor subtype. J Med Chem. 1986 Jul;29(7):1284–1288. doi: 10.1021/jm00157a029. [DOI] [PubMed] [Google Scholar]
  12. Lavielle S., Chassaing G., Ploux O., Loeuillet D., Besseyre J., Julien S., Marquet A., Convert O., Beaujouan J. C., Torrens Y. Analysis of tachykinin binding site interactions using constrained analogues of tachykinins. Biochem Pharmacol. 1988 Jan 1;37(1):41–49. doi: 10.1016/0006-2952(88)90753-8. [DOI] [PubMed] [Google Scholar]
  13. Lee C. M., Campbell N. J., Williams B. J., Iversen L. L. Multiple tachykinin binding sites in peripheral tissues and in brain. Eur J Pharmacol. 1986 Nov 4;130(3):209–217. doi: 10.1016/0014-2999(86)90270-0. [DOI] [PubMed] [Google Scholar]
  14. Lee C. M., Javitch J. A., Snyder S. H. 3h-substance P binding to salivary gland membranes. Regulation by guanyl nucleotides and divalent cations. Mol Pharmacol. 1983 May;23(3):563–569. [PubMed] [Google Scholar]
  15. Lembeck F., Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol. 1979 Dec;310(2):175–183. doi: 10.1007/BF00500282. [DOI] [PubMed] [Google Scholar]
  16. Mastrangelo D., Mathison R., Huggel H. J., Dion S., D'Orléans-Juste P., Rhaleb N. E., Drapeau G., Rovero P., Regoli D. The rat isolated portal vein: a preparation sensitive to neurokinins, particularly neurokinin B. Eur J Pharmacol. 1987 Feb 24;134(3):321–326. doi: 10.1016/0014-2999(87)90363-3. [DOI] [PubMed] [Google Scholar]
  17. Masu Y., Nakayama K., Tamaki H., Harada Y., Kuno M., Nakanishi S. cDNA cloning of bovine substance-K receptor through oocyte expression system. 1987 Oct 29-Nov 4Nature. 329(6142):836–838. doi: 10.1038/329836a0. [DOI] [PubMed] [Google Scholar]
  18. Nicoll R. A., Schenker C., Leeman S. E. Substance P as a transmitter candidate. Annu Rev Neurosci. 1980;3:227–268. doi: 10.1146/annurev.ne.03.030180.001303. [DOI] [PubMed] [Google Scholar]
  19. Payan D. G., Brewster D. R., Goetzl E. J. Specific stimulation of human T lymphocytes by substance P. J Immunol. 1983 Oct;131(4):1613–1615. [PubMed] [Google Scholar]
  20. Payan D. G., Brewster D. R., Goetzl E. J. Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts. J Immunol. 1984 Dec;133(6):3260–3265. [PubMed] [Google Scholar]
  21. Pernow B. Substance P. Pharmacol Rev. 1983 Jun;35(2):85–141. [PubMed] [Google Scholar]
  22. Regoli D., Drapeau G., Dion S., Couture R. New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization. Trends Pharmacol Sci. 1988 Aug;9(8):290–295. doi: 10.1016/0165-6147(88)90013-2. [DOI] [PubMed] [Google Scholar]
  23. Rosell S., Björkroth U., Xu J. C., Folkers K. The pharmacological profile of a substance P (SP) antagonist. Evidence for the existence of subpopulations of SP receptors. Acta Physiol Scand. 1983 Mar;117(3):445–449. doi: 10.1111/j.1748-1716.1983.tb00019.x. [DOI] [PubMed] [Google Scholar]
  24. SIEGMUND E., CADMUS R., LU G. A method for evaluating both non-narcotic and narcotic analgesics. Proc Soc Exp Biol Med. 1957 Aug-Sep;95(4):729–731. doi: 10.3181/00379727-95-23345. [DOI] [PubMed] [Google Scholar]
  25. Sandberg B. E., Iversen L. L. Substance P. J Med Chem. 1982 Sep;25(9):1009–1015. doi: 10.1021/jm00351a001. [DOI] [PubMed] [Google Scholar]
  26. Saria A., Lundberg J. M., Skofitsch G., Lembeck F. Vascular protein linkage in various tissue induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. Naunyn Schmiedebergs Arch Pharmacol. 1983 Nov;324(3):212–218. doi: 10.1007/BF00503897. [DOI] [PubMed] [Google Scholar]
  27. Shigemoto R., Yokota Y., Tsuchida K., Nakanishi S. Cloning and expression of a rat neuromedin K receptor cDNA. J Biol Chem. 1990 Jan 15;265(2):623–628. [PubMed] [Google Scholar]
  28. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  29. V Euler U. S., Gaddum J. H. An unidentified depressor substance in certain tissue extracts. J Physiol. 1931 Jun 6;72(1):74–87. doi: 10.1113/jphysiol.1931.sp002763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wormser U., Laufer R., Hart Y., Chorev M., Gilon C., Selinger Z. Highly selective agonists for substance P receptor subtypes. EMBO J. 1986 Nov;5(11):2805–2808. doi: 10.1002/j.1460-2075.1986.tb04571.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yokota Y., Sasai Y., Tanaka K., Fujiwara T., Tsuchida K., Shigemoto R., Kakizuka A., Ohkubo H., Nakanishi S. Molecular characterization of a functional cDNA for rat substance P receptor. J Biol Chem. 1989 Oct 25;264(30):17649–17652. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES